spacer
home > ebr > summer 2002 > where is the blockbuster market heading?
PUBLICATIONS
European Biopharmaceutical Review

Where is the Blockbuster Market Heading?

The success of large pharmaceutical companies primarily reflects their development and marketing of blockbuster drugs - products that achieve annual revenues in excess of US$1 billion. This has led companies to follow growth strategies that rely heavily on finding new blockbusters, rightly believing that these products can offer significantly higher returns than their lower value counterparts. Increasing sales potential is critical as the average cost of developing a new molecular entity is currently approximately US$637 million. Coupled with the fact that only one in 5,000 to 10,000 lead compounds eventually reaches market after 14 years in R&D and regulatory reviews, a drug with annual revenues above US$1 billion is clearly able to recover a greater proportion of these costs. This improves R&D productivity and contributes to company margin growth.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Linda McNamara, Healthcare Strategy Analyst at Datamonitor

Dr Linda McNamara is a Healthcare Strategy Analyst at Datamonitor. Her work has appeared in the Wall Street Journal, Forbes and MedAd News. Prior to this position, she managed the musculoskeletal and central nervous system 'real-time knowledge' platforms from the onset of a Datamonitor/Sela joint venture, analysing clinical and commercial current affairs.
Before joining Datamonitor, Linda managed a neurosurgical regional unit in a major London teaching hospital for four years. She holds a PhD in Chemistry from University College London, and has written for the academic publications Tetrahedron Letters and Journal of Organic Chemistry.

spacer
Dr Linda McNamara
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health Launches Partner Program to Team with Clinical Research Organizations (CROs) Committed to Improving Clinical Trials with Patient-Centric Technology

PHILADELPHIA August 12, 2019: Signant Health (signanthealth.com), a leading provider of technology for clinical research, today launches the Signant Health Partner Program, a significant investment the company is making to enable clinical research organizations (CROs) to better serve sponsors in the areas of Patient Data, Patient Experience, Clinical Supplies, and Endpoint Quality Solutions. By becoming a Signant Partner, CROs will benefit from new commercial and operational advantages that only come with membership.
More info >>

White Papers

The Role of the CRO in Effective Risk-Based Monitoring

Medpace

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement